prikaz prve stranice dokumenta Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series
  Download
PDF 283.64 KB
Scientific paper - Case study
Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series
Pharmacy, 11 (2023), 1; 29. https://doi.org/10.3390/pharmacy11010029
Šimičević, Livija; Slišković, Ana Marija; Vrkić Kirhmajer, Majda; Ganoci, Lana; Holik, Hrvoje; Palić, Jozefina; Samardžić, Jure; Božina, Tamara

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Šimičević, L., Slišković, A. M., Vrkić Kirhmajer, M., Ganoci, L., Holik, H., Palić, J. ... Božina, T. (2023). Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series. Pharmacy, 11. (1). doi: 10.3390/pharmacy11010029

Šimičević, Livija, et al. "Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series." Pharmacy, vol. 11, no. 1, 2023. https://doi.org/10.3390/pharmacy11010029

Šimičević, Livija, Ana Marija Slišković, Majda Vrkić Kirhmajer, Lana Ganoci, Hrvoje Holik, Jozefina Palić, Jure Samardžić and Tamara Božina. "Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series." Pharmacy 11, no. 1 (2023). https://doi.org/10.3390/pharmacy11010029

Šimičević, L., et al. (2023) 'Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series', Pharmacy, 11(1). doi: 10.3390/pharmacy11010029

Šimičević L, Slišković AM, Vrkić Kirhmajer M, Ganoci L, Holik H, Palić J, and sur.. Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series. Pharmacy [Internet]. 2023 February 05 [cited 2024 November 29];11(1). doi: 10.3390/pharmacy11010029

L. Šimičević, et al., "Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series", Pharmacy, vol. 11, no. 1, February 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:385266. [Accessed: 29 November 2024]

Metadata
Title (english)Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series
AuthorLivija Šimičević
AuthorAna Marija Slišković
AuthorMajda Vrkić Kirhmajer
AuthorLana Ganoci
AuthorHrvoje Holik
AuthorJozefina Palić
AuthorJure Samardžić
AuthorTamara Božina
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Non-vitamin K antagonist oral anticoagulants' interindividual trough concentration variability affects efficacy and safety, especially in bleeding events. Rivaroxaban is metabolised via CYP3A4/5-, CYP2J2-, and CYP-independent mechanisms and is a substrate of two transporter proteins: ABCB1 (MDR1, P-glycoprotein) and ABCG2 (BCRP; breast-cancer-resistance protein). The polymorphisms of these genes may possibly affect the pharmacokinetics of rivaroxaban and, consequently, its safety profile. Rivaroxaban variability may be associated with age, liver and kidney function, concomitant illness and therapy, and pharmacogenetic predisposition. This case series is the first, to our knowledge, that presents multiple risk factors for rivaroxaban-related bleeding (RRB) including age, renal function, concomitant diseases, concomitant treatment, and pharmacogenetic data. It presents patients with RRB, along with their complete clinical and pharmacogenetic data, as well as an evaluation of possible risk factors for RRB. Thirteen patients were carriers of ABCB1, ABCG2, CYP2J2, and/or CYP3A4/5 gene polymorphisms. Possible drug-drug interactions with increased bleeding risk were identified in nine patients. Six patients had eGFR <60 mL/min/1.73 m2. Our data suggest a possible role of multiple factors and their interactions in predicting RRB; however, they also indicate the need for further comprehensive multidisciplinary research to enable safer use of this product based on a personalised approach.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titlePharmacy
Numberingvol. 11, no. 1, 29
e-ISSN2226-4787
DOIhttps://doi.org/10.3390/pharmacy11010029
URN:NBNurn:nbn:hr:105:385266
Publication2023-02-05
ProjectNumber: UIP-2020-02-8189
Title (croatian): Uloga farmakogenomike u predviđanju nuspojava kardiovaskularnih lijekova
Title (english): Pharmacogenomics in prediction of cardiovascular drugs adverse reaction
Acronym: PGx-CardioDrug
Leader: Tamara Božina
Jurisdiction: Croatia
Funding stream: UIP
Document URLhttps://www.mdpi.com/2226-4787/11/1/29
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-01-15 08:59:15